drugset / Trial / NCT01407471

Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy

NCT01407471

RandomizedCrossoverQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether spironolactone could significantly reduce cutaneous atrophy due to corticosteroids.

Timeline

Start
2011-09
Primary completion
2012-05
Completion
2012-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clobetasol Small molecule 0.05 % Topical
Subject Spironolactone Small molecule 5 % Topical

Indications